GWP.L Share News (GWP)

BUZZ-GW Pharmaceuticals: Positive results from late-stage trial

** Drug developer GW Pharmaceuticals' shares up 22.8 pct, best day in 3 mths and at 9 mth highs, after saying a late-stage trial of its epilepsy drug met its main goal ** Co says its experimental drug Epidiolex reduced the occurence of drop-seizures in patients with Lennox-Gastault syndrom

GW Pharma succeeds with second epilepsy trial for Epidiolex

(ShareCast News) - GW Pharmaceuticals has revealed its cannabis-derived treatment has been found to reduce seizures for two forms of epilepsy. Phase III pivotal trials for its Epidiolex drug in the treatment of Lennox-Gastaut Syndrome, a rare and severe form of childhood-onset epilepsy, achieved the

GW Pharmaceuticals Sees Positive Phase III Trial Results For Epidiolex

GW to trial cannabinoid therapy on infantile spasms

(ShareCast News) - Biopharmaceutical company GW Pharmaceuticals announced on Tuesday that it has selected infantile spasms as the fourth target indication for its Epidiolex orphan pediatric epilepsy development programme. The AIM-traded firm, which focuses on discovering, developing and commercialis

GW Pharmaceuticals Targets Infantile Spasms For Epidiolex Development

REFILE-UPDATE 1-Swiss biotech AC Immune taps U.S. IPO to fund Alzheimer's drugs

(Fixes date) June 1 (Reuters) - Switzerland's AC Immune, which already has money in hand from Roche for its most advanced drug, is planning a share sale in the United States to raise up to $50 million for separate drug candidates targeting Alzheimer's disease. The company, run by form

DIRECTOR DEALINGS: GW Pharmaceuticals Non-Executive Sells Shares

GW Pharmaceuticals First Half Loss Widens, Epidolex Progress Continues

Earnings, Trading Statements Calendar - Week Ahead

GW Pharma wins US orphan status for tuberous sclerosis complex drug

(ShareCast News) - GW Pharmaceuticals has received 'orphan drug' designation from the US regulator for the company's cannabis-derived treatment for a rare genetic disorder. Gaining orphan status can smooth a drug's path to full approval and can entitle a drug to a seven-year exclusive marketing peri

GW Pharmaceuticals Gets Orphan Drug Designation For Tuberous Sclerosis

GW Pharma Starts Phase III Epidiolex Trials In Third Indication

U.S. firms target investment in Israeli cannabis R&D

* Israel focuses attention on cannabis research * U.S. marijuana market growing but research stunted * Investment in Israel expected to double in 2016 By Maayan Lubell TEL AVIV, March 29 (Reuters) - Already a pioneer in high-tech and cutting-edge agriculture, Israel is sta

AGM, EGM Calendar - Week Ahead

LONDON MARKET CLOSE: Oil Down After OPEC Cuts Its 2016 Demand Outlook